# Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site

> **NCT00193609** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 48 (actual)

## Conditions studied

- Neoplasms, Unknown Primary

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00193609
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2008-04
- **Final completion:** 2009-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2013-11-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193609, "Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00193609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*